Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists

AIDS Reviews

Volumn 14, Issue 3, 2012, Pages 208-217

  Poveda, Eva ^a   Paredes, Roger ^b   Moreno, Santiago ^c   Alcamí, José ^d   Córdoba, Juan ^e   Delgado, Rafael ^f   Gutiérrez, Félix ^g   Llibre, Josep M ^b   Deltoro, Miguel García ^h   Hernández Quero, José ⁱ   Pulido, Federico ^f   Iribarren, José Antonio ^j   García, Federico ⁱ  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f Universidad Complutense   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^j HOSPITAL DONOSTIA   (Spain)

more..

Author keywords

CCR5 antagonists; HIV tropism; Maraviroc; V3 genotyping

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; MARAVIROC; VIRUS DNA; VIRUS RNA;

ALGORITHM; ANTIVIRAL ACTIVITY; BIOASSAY; DRUG TREATMENT FAILURE; ENHANCED SENSITIVITY TROPISM ASSAY; GENETIC PROCEDURES; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DECISION MAKING; MEDICAL DEVICE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREDICTIVE VALUE; PYROSEQUENCING; REVIEW; TREATMENT RESPONSE; VIRAL TROPISM; VIRUS MUTANT;

CLINICAL TRIALS AS TOPIC; CYCLOHEXANES; FEMALE; GENOTYPE; HIV FUSION INHIBITORS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; PHENOTYPE; RECEPTORS, CCR5; TRIAZOLES; VIRAL TROPISM;

EID: 84864658614     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Comier E, Dragic T. The crown and stem of the V3 loop play distinct roles in HIV type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol. 2002;76:8953-7. (Pubitemid 34864089)
2. Berger E, Doms R, Fenyö E, et al. A new classification for HIV-1. Nature. 1998;391:240.
3. Anonymous. FDA approves maraviroc tablets. AIDS Patient Care STDs. 2007;21:702.
4. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-HIV type 1 activity. Antimicrob Agents Chemother. 2005;49:4721-32. (Pubitemid 41552605)
5. Cooper D, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010;201:803-13.
6. Fätkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008;359:1442-55.
7. Saag M, Goodrich J, Fätkenheuer G, et al. A double-blind, placebocontrolled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis. 2009;199:1638-47.
8. Poveda E, Briz V, Quinones-Mateu M, Soriano V. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS. 2006;20:1359-67. (Pubitemid 43948242)
9. Perez-Olmeda M, Poveda E. Methods for determining viral tropism: genotype and phenotype tests. Enferm Infecc Microbiol Clin. 2008;(Suppl 11):40-8.
10. Whitcomb J, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother. 2007;51:566-75. (Pubitemid 46185274)
11. Jensen M, Van't Wout A. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev. 2003;19:145-9.
12. McGovern R, Thielen A, Mo T, et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS. 2010;24:2517-25.
13. McGovern R, Dong W, Zhong X, et al. Population-based sequencing of the V3-loop is comparable to the enhanced sensitivity trofile assay in predicting virologic response to maraviroc of treatment-naive patients in the MERIT trial. 17th CROI 2010, San Francisco [Abstract 92].
14. Brumme C, Wilkin T, Su Z, et al. Relative performance of ESTA, Trofile, 454 Deep sequencing, and "reflex" testing for HIV tropism in the MOTIVATE screening population of therapy-experienced patients. 18th CROI 2011, Boston [Abstract 666].
15. Obermeier M, Carganico A, Cordes C, et al. Week 96 update on the Berlin maraviroc cohort. 10th European Meeting on HIV and Hepatitis treatment strategies and antiviral drug resistance 2012, Barcelona, Spain. [Abstract P-24].
16. Seclén E, Soriano V, González M, et al. Clinical validation of genotypic HIV tropism assessment to guide the therapeutic use of CCR5 antagonists. 52nd ICAAC 2012, San Francisco.
17. Chueca N, Recio E, Macías J, et al. Proviral DNA tropism using genotypic tools can identify responders to a maraviroc/ boosted darunavir dual therapy regimen. 10th European Meeting on HIV and Hepatitis treatment strategies and antiviral drug resistance 2012. Barcelona, Spain. [Abstract P-67].
18. Bellecave P, Paredes R, Anta L, et al. Determination of HIV-1 tropism from proviral HIV-1 DNA in patients with suppressed plasma HIV-1 RNA using population based- and deep-sequencing: impact of X4-HIV variants on virologic response to maraviroc. International Workshop on HIV and hepatitis virus drug resistance and curative strategies 2012. Sitges, Spain. [Abstract A53].
19. Low A, Dong W, Chan D, et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS. 2007;21:F17-24. (Pubitemid 47329758)
20. Chueca N, Garrido C, Alvarez M, et al. Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. J Med Virol. 2009;81:763-7.
21. Poveda E, Seclén E, González M, et al. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother. 2009;63:1006-10.
22. Sánchez V, Masiá M, Robledano C, Padilla JM, Gutiérrez F. Performance of genotypic algorithms for predicting HIV-1 tropism measured against the enhanced-sensitivity Trofile coreceptor tropism assay. J Clin Microbiol. 2010;48:4135-9.
23. Sanchez V, Masiá M, Robledano C, et al. A highly sensitive and specific model for predicting HIV-1 tropism in treatment-experienced patients combining V3 loop sequences interpretation and clinical parameters. J Acquir Immune Defic Syndr. 2011;56:51-8.
24. Poveda E, Alcamí J, Paredes R, et al. Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev. 2011;12:135-48.
25. Vandekerckhove L, Wensing AM, Kaiser R, et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis. 2011;11:394-407.
26. Trinh L, Han D, Huang W, et al. Technical validation of an enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. Antiviral Ther. 2008;13(Suppl 3):A128.
27. Sax P. Report from the 2008 joint ICAAC/IDSA meeting. Maraviroc vs. efavirenz: a reanalysis of MERIT. AIDS Clin Care. 2008;98:104.
28. Brumme C, Wilkin T, Su Z, et al. Relative performance of ESTA, Trofile, 454 Deep sequencing, and "reflex" testing for HIV tropism in the MOTIVATE screening population of therapy-experienced patients. 18th CROI 2011, Boston. [Abstract 666].
29. th European HIV Drug Resistance Workshop 2007. Cascais, Portugal. [Abstract 60]
30. Van Baelen K, Vandenbrouke I, Rondelez E, Van Eygen V, Vermeiren H, Stuyver L. HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays. J Virol Methods. 2007;146:61-73. (Pubitemid 350026623)
31. Poveda E, Rodés B, Labernardière JL, et al. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol. 2004;74:21-8. (Pubitemid 38988855)
32. Alcami J, Sánchez-Palomino S, García J, Gonzalez N. Novel HIV-based recombinant viral clones and use thereof in analytical methods, PCT/ES2005/000250 - (WO 2005108588, EP175241 A1, P200401116).
33. González N, Pérez-Olmeda M, Gacía-Pérez J, A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. J Antimicrob Chemother. 2010;65:2493-501.
34. Raymond S, Delobel P, Mavigner M, et al. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J Clin Virol. 2010;47:126-30.
35. Saliou A, Delobel P, Dubois M, et al. Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob Agents Chemother. 2011;55:2831-6.
36. Gonzalez-Serna A, Leal M, Genebat M, et al. TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches. J Clin Microbiol. 2010;48:4453-8.
37. Ruiz-Mateos E, González-Serna A, Genebat M, et al. Virological response after a short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors. Antimicrob Agents Chemother. 2011;55:4664-9.
38. Li W, Webb E, Nary L, Robins T. SensiTrop QT: A novel molecular diagnostic assay for the detection and quantification of HIV co-receptor tropism. 15th CROI 2008, Boston. [Abstract 919].
39. Isaka Y, Sato A, Miki S, et al. Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5. Virology. 1999;264:237-43. (Pubitemid 29531906)
40. de Jong J, Goudsmit J, Keulen W, et al. HIV-1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol. 1992;66:757-65.
41. Cardozo T, Kimura T, Philpott S, Weiser B, Burguer H, Zolla-Pazner S. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses. 2007;23:415-26. (Pubitemid 46608562)
42. Briggs D, Tuttle D, Sleasman J, Goodenow M. Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS. 2000;14:2937-9. (Pubitemid 32042758)
43. Delobel P, Nugeyre M, Cazabat M, et al. Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol. 2007;45:1572-80. (Pubitemid 46762416)
44. Hoffman NG, Seillier-Moiseiwitsch F, Anh J, Walker JM, Swanstrom R. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol. 2002;76:3852-64. (Pubitemid 34250550)
45. Sierra S, Kaiser R, Thielen A, Lengauer T. Genotypic coreceptor analysis. Eur J Med Res. 2007;12:453-62. (Pubitemid 350011458)
46. Pillai S, Good B, Richman D, Corbeil J. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses. 2003;19:145-9. (Pubitemid 36308052)
47. Sing T, Low A, Beerenwinkel N, et al. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther. 2007;12:1097-106. (Pubitemid 350114990)
48. Jensen M, Li F, van't Wout A, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol. 2003;77:13376-88. (Pubitemid 37494331)
49. Jensen M, Coetzer M, van't Wout A, Morris L, Mullins J. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol. 2006;80:4698-704.
50. Schapiro J, Boucher C, Kuritzkes D, et al. Baseline CD4+ T cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients. Antivir Ther. 2011;16:395-404.
51. th Annual Meeting, Washington, DC. [Abstract H-1221].
52. Recomendaciones de Gesida/Plan Nacional sobre el SIDA respecto al tratamiento antiretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2012). http://www.gesida. seimc.org.
53. Geretti A, Mackie N. Determining HIV-1 tropism in routine clinical practice. http://www.bhiva.org/documents/Guidelines/Tropism/HIV-1Tropism.doc
54. European tropism guidelines. http://www.europehivresistance.org.
55. Panel on Antiretroviral Guidelines for Adults and Adolescents 2012. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL.pdf.
56. European AIDS Clinical Society 2011. Guidelines-clinical management and treatment of HIV infected adults in Europe. http://www. europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/1-treatment-of-hiv- infected-adults.pdf.
57. Seclén E, del Mar González M, De Mendoza C, Soriano V, Poveda E. Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viremia. J Antimicrob Chemother. 2010;65:1493-6.
58. Obermeier M, Walter H, Korn K, et al. Multicenter comparison of genotypic tropism testing: results from viral RNA and proviral DNA. 9th European Workshop on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance 2011, Paphos, Cyprus. [Abstract O-21].
59. Verhofstede C, Brudney D, Reynaerts J, et al. Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. HIV Med. 2011;12:544-52.
60. th European Meeting on HIV & Hepatitis treatment strategies & antiviral drug resistance 2012. Barcelona, Spain. [Abstract O-17].
61. th European Meeting on HIV & Hepatitis treatment strategies & antiviral drug resistance 2012. Barcelona, Spain. [Abstract P-28].
62. th European Meeting on HIV & Hepatitis treatment strategies & antiviral drug resistance 2012. Barcelona, Spain. [Abstract O-16].
63. Seclén E, Soriano V, González M, Gómez S, Thielen A, Poveda E. High concordance between PSSM and geno2pheno algorithms for genotypic interpretation of HIV-1 tropism- V3 length as the major cause of disagreement. J Clin Microbiol. 2011;49:3380-2.
64. Swenson L, Knapp D, Harrigan R. Calibration and accuracy of the geno2pheno co-receptor algorithm for predicting HIV tropism for single and triplicate measurements of V3 genotype. J Int AIDS Soc. 2010; 13(Suppl 4):O8.
65. Seclén E, Poveda E, González M, et al. High sensitivity to detect X4 variants using specific genotypic tools in antiretroviral-experienced HIV patients suitable to CCR5 antagonists therapy. J Antimicrob Chemother. 2010;65:1486-92.
66. Raymond S, Delobel P, Mavigner M, et al. Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol. 2009;47:2292-4.
67. Raymond S, Delobel P, Mavigner M, et al. Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. J Acquir Immune Defic Syndr. 2010;53:167-75.
68. Treviño A, Soriano V, Rodríguez C, et al. Changing rate of non-B subtypes and coinfection with hepatitis B/C viruses in newly diagnosed HIV type 1 individuals in Spain. AIDS Res Hum Retroviruses. 2011;27:633-8.
69. Leoz M, Chaix M, Delaugerre C, et al. Circulation of multiple patterns of unique recombinant forms B/CRF02-AG in France precursor signs of the emergence of an upcoming CRFB/02. AIDS. 2011;25:1371-7.
70. Buonaguro L, Tornesello M, Buonaguro F. HIV-1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol. 2007;81:10209-19. (Pubitemid 47463296)
71. th European HIV Drug Resistance Workshop 2010, Sorrento, Italy. [Abstract 20].
72. th CROI 2011, Boston [Abstract 668].
73. Margulies M, Egholm M, Altman W, Attiya S, Bader J, Bemben L, Genome sequencing in microfabricated high-density picolitre reactors. Nature. 2005;437:376-80. (Pubitemid 41613494)
74. Swenson L, Dong W, Mo T, et al. Deep sequencing to infer HIV-1 coreceptor usage: application to three clinical trials of maraviroc in treatment-experienced pateints. J Infect Dis. 2011;203:237-45.
75. Swenson L, Mo T, Dong W, et al. Deep V3 sequencing for HIV type 1 tropism in treatment-naïve patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis. 2011;53:732-42.
76. th CROI 2011, Boston [Abstract 669].